Seres therapeutics presents preclinical research on investigational microbiome therapeutic ser-155 at the 2022 european bone marrow transplantation annual meeting

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the european bone marrow transplantation (ebmt) annual meeting that suggest ser-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (hsct) to avoid infection or graft-versus-host disease (gvhd), which currently afflict about half of this patient population
MCRB Ratings Summary
MCRB Quant Ranking